Activated estrogen receptor‐mitogen‐activated protein kinases cross talk confer acquired resistance to lapatinib
نویسندگان
چکیده
منابع مشابه
Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib
BACKGROUND The efficacy of lapatinib is limited by the development of acquired resistance. The aim of this study was to investigate the role of estrogen receptor (ER) signaling compensatory activation in acquired resistance to lapatinib in breast cancer cells BT474 and the related mechanism. METHODS Acquired resistant cell model resistant (r)BT474 was generated with an increasing concentratio...
متن کاملCross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
Background: Usually, chemoradiotherapy can be used for the treatment of locally advanced colorectal cancer (CRC) before surgery. On the other hand, some studies have shown that fractional radiation of tumor cells leads to chemoresistance. The aim of this study was to evaluate the chemoresistance of radioresistant sub-line (RR sub-line).Methods: This study was done in Hamadan University of...
متن کاملIs acquired activated protein C resistance a cardiovascular risk?
Cardiovascular Risk? To the Editor: We have read the article by Kiechl et al1 demonstrating that acquired activated protein C resistance (APC) may be a risk factor for atherosclerosis and arterial thrombosis in whites. We2 previously demonstrated that acquired APC resistance is associated not only with venous thrombosis (deep vein thrombosis and pulmonary thromboembolism) but also with arterial...
متن کاملAcquired activated protein C resistance caused by lupus anticoagulants.
Lupus anticoagulants (LA) can cause acquired activated protein C resistance (APC-R), but the clinical significance is unclear. To investigate thrombosis and acquired APC-R in patients with LA, we enrolled all 132 patients undergoing hypercoagulability testing with positive LA results and in whom APC-R (with factor V-deficient plasma) was performed during a 2.5-year period. Among 121 patients wi...
متن کاملERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
The use of targeted therapeutics directed against BRAF(V600)-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge. By far, the most common clinical resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms. Thus, targeting ERK itself has emerged as an attr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thoracic Cancer
سال: 2015
ISSN: 1759-7706,1759-7714
DOI: 10.1111/1759-7714.12239